Hannelore G. Denys

Gent, VLG, BE

Expertise in

conditions

Gent, VLG, BE

OverviewLocationsClinical Research

Overview

Hannelore Denys practices in Gent, Belgium. Ms. Denys is highly rated in 6 conditions, according to our data. Her top areas of expertise are Cervical Cancer, Ovarian Cancer, Breast Cancer, Hysterectomy, and Mastectomy.

Her clinical research consists of co-authoring 113 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Gent, VLG, Belgium

Other Locations

Antwerpen, VLG, Belgium

Leuven, VLG 3000, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer

Enrollment Status: Active_not_recruiting

Publish Date: October 14, 2025

Intervention Type: Drug

Study Drugs: Tisotumab Vedotin, Bevacizumab, Pembrolizumab, Carboplatin

Study Phase: Phase 1/Phase 2

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 15, 2025

Intervention Type: Drug

Study Drugs: Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed

Study Phase: Phase 3

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy

Enrollment Status: Terminated

Publish Date: July 15, 2025

Intervention Type: Drug

Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy

Study Phase: Phase 3

EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy

Enrollment Status: Active_not_recruiting

Publish Date: July 11, 2025

Intervention Type: Drug

Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib

Study Phase: Phase 3

A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Enrollment Status: Active_not_recruiting

Publish Date: January 29, 2025

Intervention Type: Drug

Study Drugs: VS-6766, Defactinib

Study Phase: Phase 2

Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2024

Intervention Type: Drug

Study Drugs: Entrectinib, Letrozole, Goserelin

Study Phase: Phase 2

SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression